Tomas Neilan, MD
Enriched profileAssociate Professor of Medicine, Harvard Medical School; Director, Cardio-Oncology Program, Massachusetts General Hospital; Co-Director, Cardiovascular Imaging Research Center (CIRC), MGH · Massachusetts General Hospital
Tomas Neilan is Associate Professor of Medicine, Harvard Medical School; Director, Cardio-Oncology Program, Massachusetts General Hospital; Co-Director, Cardiovascular Imaging Research Center (CIRC), MGH at Massachusetts General Hospital. OpenAlex indexes 407 publications with 21,774 citations (h-index 70); ClinicalTrials.gov lists 3 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Cardiovascular Disease profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Tomas Neilan, MD, is Associate Professor of Medicine, Harvard Medical School at Massachusetts General Hospital. The public record shows 407 publications with 21,774 citations (h-index 70), centered on Chemotherapy-induced cardiotoxicity and mitigation, Cardiac Imaging and Diagnostics, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 10 companies, 5 NIH-funded awards (2016–2026).
- Most recent indexed publication: 2026 · Journal of the American Heart Association
- Top research focus: Chemotherapy-induced cardiotoxicity and mitigation
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 10 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 19 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 182.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)
Sponsor: Massachusetts General Hospital
- Cardiac Fibrosis by CMR in Patients With Cancer
Sponsor: Massachusetts General Hospital
Industry payments
Updated 27 Aug 2026
10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20254 payments$40,640openpaymentsdata.cms.gov ↗
- GlaxoSmithKline, LLC.Program year20253 payments
- E.R. Squibb & Sons, L.L.C.Program year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
87.9%Statin27.9%Atorvastatin Calcium61%Rosuvastatin Calcium33%Pravastatin Sodium6%Part D<11 patientsBeta blocker18.8%Metoprolol Succinate75%Carvedilol26%Part D≥78 patientsBlood & clotting
8.1%Factor Xa inhibitor6.8%Eliquis100%Part D≥36 patientsP2Y12 inhibitor1.3%Clopidogrel100%Part D<11 patientsMetabolism & gastrointestinal
4%SGLT2 inhibitor3.3%Jardiance100%Part D≥19 patientsPotassium supplement0.6%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
5 NIH research awards on record, funded 2016–2026 per NIH RePORTER. The latest:
- Immune checkpoint inhibitors and accelerated coronary atherosclerosis
Massachusetts General Hospital
FY2026$1,145,094R01HL159187 - Immune checkpoint inhibitors and accelerated coronary atherosclerosis
Massachusetts General Hospital
FY2025$1,023,526R01HL159187 - Cardiovascular Diseases among Patients with Cancer and Patients living with HIV
Massachusetts General Hospital
FY2025$133,685K24HL150238
Congress activity
Updated 27 Aug 2026
21 congress contributions (2018–2026) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 4790: Cancer reprograms the remote vascular microenvironment to promote atherosclerosis
AACR Annual Meeting
AACR2026Co-author - Abstract 7474: T-cell responses across heart, blood, and tumor in patients with immune checkpoint inhibitor-related myocarditis (irMyocarditis)
AACR Annual Meeting
AACR2024Co-author - Detection of immune-related adverse events among hospitalized patients using large language models.
ASCO Annual Meeting
ASCO2024Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer.
Journal of the American Heart Association
Article2026 - Immune checkpoint inhibitors and myocardial infarction.
Journal of thrombosis and thrombolysis
Review2026 - Predictors of Long-Term Survival in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis.
Journal of the American Heart Association
Article2025 - Associations Between Social Determinants of Health, Allostatic Load, and Anthracycline Cardiotoxicity in a Diverse Patient Population.
Journal of the American Heart Association
Article2025
Most-cited works
by citation count (OpenAlex)- 01
- 02Myocarditis in Patients Treated With Immune Checkpoint InhibitorsArticle1,557 citations2018
- 03Efficacy of Tocilizumab in Patients Hospitalized with Covid-19Article1,436 citations2020
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
aimssummit.com/team/tom-neilan
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aimssummit.com ↗ - Other
ic-os.org/find-a-cardiooncologist/tomas-neilan-md-mph
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ic-os.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD (MBBCH, BAO)
University College Dublin Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cvrc.massgeneral.org ↗ - MPH
Harvard T.H. Chan School of Public Health
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cvrc.massgeneral.org ↗ - Board Certified
Internal Medicine, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗
Editorial & leadership roles
journal and society appointmentsAwards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irishamerica.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cvrc.massgeneral.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cvrc.massgeneral.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org ↗
- Associate Director
MGH T32 Training Program in Cardiovascular Imaging
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →acc.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ic-os.org ↗
- CardioNerds Podcast
Episode 365: "CardioOncology: Cardiotoxicity of Novel Immunotherapies with Dr. Tomas Neilan"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cardionerds.com ↗ - Contributor
Mass General Advances in Motion (patient/physician education video and article series)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →advances.massgeneral.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
James Januzzi, MD
Massachusetts General Hospital
Maurizio Fava, MD
Massachusetts General Hospital
Steven Greenberg, MD
Massachusetts General Hospital
David Scadden, MD
Massachusetts General Hospital